The DEA has moved CBD prescription drugs with THC levels below .01% to a Schedule 5 drug after the FDA’s approval of Epidolex. However, despite the reschedule, cannabis still remains a Schedule 1 substance. READ MORE
(By accessing, browsing or using the pages below, you agree to the Blog Conditions of Use/Disclaimer available under "Links.")
Contributors
Contributors
RELATED EVENTS
RELATED EVENTS
August 27
2019
2019
Posts
Hazy outlook for legislation protecting medical cannabis
October 18, 2017
The fate of crucial federal legislation protecting medical cannabis producers, retailers and consumers from prosecution by the U.S. Department of Justice has recently become uncertain due to differences in House and Senate spending legislation. READ MORE
DEA awards Schedule II classification to synthetic THC drug
Kevin Young
April 4, 2017
The DEA has applied a stricter scheduling classification to a new cannabis-containing drug than a similar drug already on the market. What can be read into this decision and how will it affect the future development of cannabis pharmaceuticals? READ MORE
The silver lining in the DEA’s refusal to reclassify cannabis
August 15, 2016
Although the DEA announced last week that it would not reschedule cannabis, the decision did come with promising news of enhanced research opportunities that could bolster the cannabis industry's long-term growth. READ MORE
Thompson Coburn advises clients on state laws governing the business of cannabis to facilitate compliance with those state laws. Federal laws concerning cannabis currently conflict with state laws in states that have legalized cannabis or possession of cannabis. Although federal enforcement policy may at times defer to these states’ laws and not enforce conflicting federal laws, interested businesses and individuals should be aware that compliance with state law in no way assures compliance with federal law, and there is a risk that conflicting federal laws may be enforced in the future. In addition to this Cannabis-specific note, readers should review Thompson Coburn’s Conditions of Use / Disclaimers page containing other important information.